New pill takes on tough blood cancers in early trial
NCT ID NCT06846606
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tests an oral drug called AUTX-703 in 34 adults with relapsed or hard-to-treat acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The main goal is to check safety and find the right dose. It's an open-label trial, meaning everyone knows they're getting the drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AUTX-703 (oral drug)
- What this could lead to
- If successful, this could point toward a new treatment option for people with hard-to-treat blood cancers like AML and MDS.
- What could go wrong
- This is a very early Phase 1 trial with only 34 participants, so it's mainly checking safety and dosing. It may not show strong anti-cancer effects, and side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope National Medical Center
Duarte, California, 91010, United States
-
H Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10021, United States
-
Ohio State University, The James Comprehensive Cancer
Columbus, Ohio, 43210, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14203, United States
-
Sarah Cannon Center for Blood Cancer at TriStar Centennia
Nashville, Tennessee, 37203, United States
-
UPENN Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania, 19104, United States
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27514, United States
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Weekly pill cocktail aims to tame resistant blood cancers
- Promising Three-Drug cocktail targets Hard-to-Treat leukemia
- New hope for AML patients who fail venetoclax?
- New hope for tough blood cancers: first human trial launches
- New Antibody-Drug conjugate takes aim at tough leukemias
- Experimental CAR t therapy takes on tough leukemia